生物医学随机试验中危害报告常不完整或不一致:一项元流行病学研究
该元流行病学研究随机抽样2023年PubMed收录的200项生物医学随机对照试验,评估危害的预先指定、报告、两者一致性、报告标准透明度及公平性相关危害报告。结果显示危害常被指定和报告,但计划与报告的一致性及报告标准透明度不足,且无试验按PROGRESS-Plus公平性因素分层报告危害。
要点
- 60.0%的试验既指定又报告危害,26.5%两者均无。
- 仅1.0%的试验明确指定危害报告标准。
- 无试验按PROGRESS-Plus公平性因素分层报告危害。
核心结论
- 在当代生物医学随机对照试验样本中,危害常被指定和报告,但计划与报告危害的一致性及报告标准的透明度仍存在不足。
研究设计与样本
- 元流行病学研究,随机抽样2023年PubMed收录的200项生物医学随机对照试验,利用公开方案、试验注册库和发表文献进行评估。
主要发现
- 64.0%(128/200)的试验在公开方案、注册库研究细节或方法部分指定了危害,69.5%(139/200)报告了危害。
- 200项试验中,120项(60.0%)既指定又报告危害,8项(4.0%)指定但未报告,19项(9.5%)未指定但报告,53项(26.5%)两者均无。
- 在既指定又报告的120项试验中,完全一致87项(72.5%),部分一致29项(24.2%),不一致4项(3.3%)。
- 仅1.0%(2/200)的试验明确指定危害报告标准,7.0%(14/200)在报告时表明使用了标准。
- 有注册库列表或可获取方案的试验指定危害的比值比分别为OR=2.1 [1.2, 3.8]和OR=5.6 [1.8, 18.1];药物试验相比行为或物理治疗试验指定和报告危害的比值比分别为OR=3.5 [1.9, 6.5]和OR=3.3 [1.7, 6.2]。
临床怎么用
- 试验研究者应在方案/注册库中预先指定危害结局,并在所有公开来源中全面、一致地报告危害。
- 当计数和收集的参与者特征支持时,可按关键公平性因素进行描述性危害总结,以帮助识别潜在脆弱性,但对罕见危害需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To characterize harms specification, harms reporting, concordance between specified and reported harms, transparency about harms reporting criteria, and equity-related harms reporting in randomized controlled trials (RCTs) of biomedical interventions. STUDY DESIGN AND SETTING: We conducted a meta-epidemiological study of 200 randomly sampled biomedical RCTs indexed in PubMed in 2023. Using publicly available protocols, trial registries, and publications, we assessed harms specification, harms reporting, concordance between specified and reported harms, transparency about harms reporting criteria, and whether trials had considered PROGRESS-Plus equity-related factors when reporting harms. RESULTS: Sixty-four percent (128/200) of the trials were registered, and 15.5% (31/200) had an accessible protocol. Harms were specified in 64.0% (128/200) across publicly available protocols, registry study details, or method section and reported in 69.5% (139/200). Across the 200 RCTs, 120 trials (60.0%) both specified and reported harms, 8 (4.0%) specified harms but reported none, 19 (9.5%) reported harms without prior specification, and 53 (26.5%) neither specified nor reported harms. Among the 120 trials that both specified and reported harms, concordance was complete in 87 trials (72.5%), partial in 29 trials (24.2%), and absent in 4 trials (3.3%). Only 1.0% (2/200) clearly specified harms reporting criteria, and 7.0% (14/200) indicated using criteria when reporting. Trials with a registry listing or an identified protocol had higher odds of specifying harms compared with trials without (OR = 2.1 [1.2, 3.8] and OR = 5.6 [1.8, 18.1], respectively). Compared with behavioral or physical therapy interventions, pharmacological trials had higher odds of harms specification (OR = 3.5 [1.9, 6.5]) and harms reporting (OR = 3.3 [1.7, 6.2]). No trials reported harms stratified by PROGRESS-Plus equity-related factors. CONCLUSION: In a contemporary sample of biomedical RCTs, harms were frequently specified and reported, but concordance between planned and reported harms and transparency about reporting criteria remain deficient. Trialists should prespecify harms outcomes in protocols/registrations and report harms comprehensively and consistently across all public sources; when counts and collected participant characteristics support it, descriptive harms summaries by key equity-related factors may help identify potential vulnerability, with cautious interpretation for rare harms. PLAIN LANGUAGE SUMMARY: Randomized trials are often used to understand how biomedical interventions work, but they should also be used to identify potential harms. In this study of 200 randomized trials published in 2023, most trials specified or reported at least one harm, but the harms planned in protocols, registries, or methods sections often did not fully match those reported in the results. Trials that were registered or had a study protocol were more likely to specify potential harms than trials without them. Drug, surgery, and medical device trials were also more likely than behavioral or physical therapy trials to both specify and report harms. Very few trials explained the criteria used to decide which harms were reported, and none reported harms by equity-related participant characteristics. Better planning for and more complete reporting of harms would help clinicians, patients, reviewers, and policymakers better judge the balance between the benefits and harms of a health intervention.
引用
- Shaughnessy D, Krishan A, Naaman K, et al. Harms reporting was frequently incomplete or discordant in biomedical randomized trials: a meta-epidemiological study. J Clin Epidemiol. 2026. PMID: 42401376. doi:10.1016/j.jclinepi.2026.112401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。